Cancer Therapy-Induced Cardiotoxicity: Results of the Analysis of the UK DEFINE Database
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Hypertension is the most common cardiovascular issue linked to non-small cell lung cancer (NSCLC) treatments. This study analyzed drug associations to understand cancer therapy cardiotoxicity risks.
Area Of Science
- Oncology
- Cardiology
- Pharmacovigilance
Background
- Novel cancer therapies require understanding cardiotoxicity for survivor health.
- Cardiotoxicity significantly impacts long-term health and quality of life for cancer survivors.
Purpose Of The Study
- To determine the association between cardiotoxicity and non-small cell lung cancer (NSCLC) treatments.
- Utilized a hospital medicines usage database in England for real-world data analysis.
Main Methods
- Retrospective observational study using UK DEFINE database.
- Extracted monthly secondary data for 40 selected drugs (April 2017 - July 2022).
Main Results
- Apixaban was most frequently associated with oncology drugs, indicating atrial fibrillation risk.
- Atenolol linked to afatinib, erlotinib, methotrexate, suggesting ischemia or hypertension.
- Verapamil associated with docetaxel, epirubicin, indicating arrhythmia or hypertension.
Conclusions
- Hypertension emerged as the most frequent cardiovascular disease associated with 20 oncology drugs.
- The study enhances understanding of specific NSCLC-treatment and cardiovascular drug pair associations.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...